SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to present at various upcoming investor and scientific conferences. Capricor management will present updates on Capricor’s recent progress on its lead program of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) as well as other general scienti ...